| Rank |
Status |
Study |
| 1 |
Recruiting
|
Management of Myocardial Injury After Noncardiac Surgery Trial
| Condition: |
Myocardial Injury After Noncardiac Surgery (MINS) |
| Interventions: |
Drug: Dabigatran; Drug: Placebo (for Dabigatran); Drug: Omeprazole; Drug: Placebo (for Omeprazole) |
| Outcome Measures: |
Major vascular complication (for Dabigatran); Major upper gastrointestinal complication (for Omeprazole); Individual secondary outcomes for Dabigatran; Upper gastrointestinal complication for Omeprazole; Major vascular complication for Omeprazole; Individual secondary outcomes for Omeprazole; Safety outcomes for Dabigatran; Safety outcomes for Omeprazole |
|
| 2 |
Unknown †
|
Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding
| Condition: |
Nonvariceal Upper Gastrointestinal Bleeding |
| Interventions: |
Drug: Intravenous Omeprazole; Drug: Oral Rabeprazole |
| Outcome Measure: |
This study aims to compare the effect of three-day oral rabeprazole and iv omeprazole on bleeding control in patients with mild to moderate non-variceal UGIB. |
|
| 3 |
Not yet recruiting
|
Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN)
| Condition: |
Acute Coronary Syndromes |
| Interventions: |
Drug: omeprazole; Drug: Pantoprazole |
| Outcome Measures: |
Platelet aggregation rate(AA 、ADP); clinical adverse events |
|
| 4 |
Recruiting
|
Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)
| Condition: |
Idiopathic Pulmonary Fibrosis |
| Interventions: |
Drug: Omeprazole; Drug: Matched placebo |
| Outcome Measures: |
objectively measured cough frequency; symptoms of cough; reflux symptoms; acid and non-acid reflux; vital capacity (VC) & transfer factor for carbon monoxide (Tco); 6 minute walk distance; assess amount of inflammation in lung; lung infection rate; adverse events rate |
|
| 5 |
Recruiting
|
Gastroesophageal Reflux Treatment in Scleroderma
| Conditions: |
Gastroesophageal Reflux Disease; Systemic Sclerosis; Scleroderma |
| Interventions: |
Drug: Alginic acid; Drug: placebo (for domperidone); Drug: Domperidone; Drug: placebo (of alginic acid) |
| Outcome Measures: |
Changing severity of heart burn and regurgitation of SSc related omeprazole resistant GERD evaluated by visual analogue score (VAS); changing of frequency of symptoms in SSc related omeprazole resistant GERD evaluated by frequency scale for the symptoms of GERD (FSSG) and the quality of life which is evaluated by EQ-5DTM (by EuroQol Group); the prevalence of omeprazole-resistant GERD in SSc after 4 weeks treatment with omeprazole |
|
| 6 |
Recruiting
|
Comparison of the Gastric Acid Suppressive Effects of Esomeprazole and Generic Omeprazole
| Condition: |
Gastric Acid |
| Interventions: |
Drug: Esomeprazole first; Drug: Generic omeprazole first |
| Outcome Measures: |
Median intragastric pH and percentage of time that intragastric pH is above 4; Nocturnal acid breakthrough, defined as at least 60 continuous minutes of intragastric pH below 4 occurring between 10pm and 6 am and adverse events |
|
| 7 |
Recruiting
|
Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia
| Conditions: |
Dyspepsia; Compliance; Depression |
| Interventions: |
Drug: Omeprazole; Drug: Flupentixol and Melitracen Tablets(for dyspepsia symptoms) + Omeprazole; Drug: Flupentixol and Melitracen Tablets(for depression symptoms) + Omeprazole; Drug: Flupentixol and Melitracen Tablets(without explanation) + Omeprazole |
| Outcome Measures: |
compliance of antidepressant medication; dyspepsia symptom questionnaire; psychiatric symptom on Hospital Anxiety and Depression Scale; quality of life rating; adverse reaction |
|
| 8 |
Unknown †
|
Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel
| Condition: |
Drug Interaction of Clopidogrel |
| Interventions: |
Drug: omeprazole; Drug: fluvoxamine; Drug: placebo |
| Outcome Measure: |
platlet reactivity in response to clopidogrel |
|
| 9 |
Recruiting
|
Melatonin Associated to Acid Inhibition for Chemoprevention in Barret Esophagus: a Pilot Study
| Condition: |
Barrett's Esophagus |
| Interventions: |
Drug: Omeprazole; Drug: Melatonin |
| Outcome Measures: |
Oxidative stress; Biological markers of diseases progression; The presence of DNA anomalies (tetraploidy and aneuploidy. |
|
| 10 |
Recruiting
|
CYP2C19 Genotype Predictor of Gastric Acid Suppression
| Condition: |
Esophagitis |
| Intervention: |
Drug: Omeprazole |
| Outcome Measures: |
The correlation specific to CYP2C19 genotype with gastric acid suppression by omeprazole.; To assess patients gastrointestinal symptoms, in patients with EoE by means of standard validated questionnaires |
|
| 11 |
Unknown †
|
Evaluation of Omeprazole Effect on Glaucoma
| Condition: |
Glaucoma |
| Interventions: |
Drug: Omeprazole; Drug: Placebo |
| Outcome Measure: |
|
|
| 12 |
Not yet recruiting
|
"Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-
| Condition: |
Coronary Artery Disease |
| Interventions: |
Drug: Pantoprazole,; Drug: Omeprazole |
| Outcome Measures: |
Assessment of platelet reaction units; Frequency of high platelet reactivity |
|
| 13 |
Not yet recruiting
|
Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC
| Condition: |
CDA Type I |
| Intervention: |
Drug: omeprazole |
| Outcome Measure: |
evaluate number of adverse effects per patient treated with LOSEC + levels of iron, ferritin,complete blood count and chemistry panel. |
|
| 14 |
Recruiting
|
Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
| Conditions: |
Gastroesophageal Reflux; Esophageal Atresia; Hernia, Diaphragmatic |
| Intervention: |
Drug: Omeprazole suppository |
| Outcome Measures: |
Therapeutic efficacy; Intragastric pH, Pharmacokinetic parameters, PK-PD-relation,; Pharmacogenetic parameters |
|
| 15 |
Unknown †
|
Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus
| Conditions: |
Barrett Esophagus; Gastroesophageal Reflux |
| Interventions: |
Drug: Zegerid (proton pump inhibitor); Procedure: Bravo pH monitoring |
| Outcome Measures: |
Control of esophageal pH; Control of GERD symptoms |
|
| 16 |
Unknown †
|
Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole
| Condition: |
Coronary Artery Disease |
| Intervention: |
|
| Outcome Measures: |
To test whether concomitant administration of omeprazole will decrease the platelet inhibitory properties of clopidogrel in subjects with loss of function (LOF) mutation of CYP2C19 (known as *2 and *3).; To test whether concomitant administration of omeprazole will decrease the conversion of clopidogrel to its active metabolite in subjects with loss of function (LOF) mutation of CYP2C19 (known as *2 and *3). |
|
| 17 |
Not yet recruiting
|
Laryngomalacia Study
| Condition: |
Laryngomalacia |
| Interventions: |
Drug: Omeprazole; Drug: Placebo |
| Outcome Measures: |
Laryngomalacia Symptom Score; Caring For a Child with Laryngomalacia Family Impact Questionnaire; Revised Infant Gastro-Esophageal Reflux Questionnaire; Reflux Finding Score; End of treatment 24-hour double-probe pH monitoring; Weight |
|
| 18 |
Not yet recruiting
|
Placebo In Chronic Pain
| Condition: |
Chronic Back Pain |
| Interventions: |
Drug: Naproxen; Drug: Placebo; Drug: Omeprazole |
| Outcome Measure: |
VAS pain scale |
|
| 19 |
Unknown †
|
Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine
| Conditions: |
Coronary Heart Disease; GI Bleeding |
| Intervention: |
Drug: PPI Platelet Inhibitory |
| Outcome Measure: |
Platelet function as assessed by a CPA system |
|
| 20 |
Not yet recruiting
|
The Effect of NSAIDs After a Rotator Cuff Repair Surgery.
| Condition: |
Rotator Cuff Tear |
| Interventions: |
Procedure: Rotator cuff repair; Drug: Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole; Drug: Hydrocodone/Acetaminophen |
| Outcome Measures: |
American Shoulder and Elbow Surgeons (ASES) Shoulder Score; Ultrasound evaluation of retear rate |
|
